Daklinza (Daclatasvir)

Brand Daklinza is availabe here.  Generic Daklinza is available at 90% discounts

Click here for information on Mylan generics (Immediate availability)

For Brand Daklinza Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine

According to the European Medicines Agency, brand name Daklinza originating from Europe is manufactured at the following site(s):Gilead Sciences Ireland UC IDA Business & Technology Park Carrigtohill County Cork Ireland

Information about Daklinza (Daclatasvir): 

Daklinza is a prescription medication used in combination with other antiviral drugs to treat chronic hepatitis C virus (HCV) infection. It belongs to a class of drugs known as direct-acting antivirals (DAAs) and works by inhibiting a specific protein (NS5A) that the hepatitis C virus needs to replicate.

Daklinza is an antiviral medication, it functions as an NS5A inhibitor, which means it targets and blocks a specific protein (NS5A) that the hepatitis C virus needs to replicate. Daklinza is indicated for use in combination with sofosbuvir, with or without ribavirin, to treat chronic HCV infection specifically in patients with genotype 1 or genotype 3.

Product Highlights:

• Often used with other antiviral agents such as sofosbuvir, sometimes with ribavirin depending on the specific HCV genotype and patient factors.
• SVR12 refers to the absence of detectable HCV RNA in the blood 12 weeks after completing treatment, indicating a successful response.
• The effectiveness of Daklinza in achieving SVR12 is reduced in patients with genotype 3 who also have cirrhosis when treated with Daklinza and sofosbuvir for 12 weeks.

Key Ingredient:

• Daclatasvir

Key Benefits:

• Proven to be effective in achieving sustained virologic response (SVR) in many patients with hepatitis C.
• Generally well-tolerated with fewer side effects compared to older therapies.
• Taken orally once daily, making it easier for patients to adhere to the treatment regimen.
• Effective against multiple genotypes of HCV when used in combination with other drugs.

Direction of Use:

• Take the tablet orally with or without food.
• The standard dosage is one 60 mg tablet once daily. Follow the specific dosage and administration instructions provided by your healthcare provider.
• Treatment duration typically ranges from 12 to 24 weeks, depending on the HCV genotype and patient characteristics.

Safety Concerns:

• Can interact with certain medications, which may affect its efficacy or increase the risk of side effects. Always inform your healthcare provider of all medications you are taking.
• Common side effects include fatigue, headache, nausea, and diarrhea. Serious side effects are rare but can include liver problems.
• Regular monitoring by a healthcare provider is recommended to track the response to treatment and manage any potential side effects.

Avoid Daklinza (Daclatasvir) If:

• You are allergic to daclatasvir or any other ingredients in the medication.
• You have severe liver disease (decompensated cirrhosis) without appropriate antiviral therapy, as it may not be suitable or effective.
• You are taking medications that have known significant interactions with daclatasvir, which could impact the effectiveness of the treatment or increase side effects.